Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

IRCT2017090133941N17 - Bifidobacterium bifidum + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei + Lactobacillus acidophilus & Type 2 diabetes (T2D) under hemodialysis

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Study overview

It is a randomized, double-blinded, placebo-controlled clinical trial studying Bifidobacterium bifidum + Inulin-type fructans (ITF) / Inulin (0.8 g/day) + Lacticaseibacillus casei + Lactobacillus acidophilus (2 × 10^9 CFU/g each bacterial strain) or placebo in 60 patients with type 2 diabetes (T2D) under hemodialysis for 12 weeks (1)

Outcome measures

Metabolic profiles (1)

Results (1)

Bifidobacterium bifidum + Inulin-type fructans (ITF) / Inulin + Lacticaseibacillus casei + Lactobacillus acidophilus has been shown to have several significant effects on metabolic and inflammatory markers when compared to a placebo. The key findings ar…

References (Sources)

The Effects of Synbiotic Supplementation on Metabolic Status in Diabetic Patients Undergoing Hemodialysis: a Randomized, Double-Blinded, Placebo-Controlled Trial
Soleimani et al. 2019 Probiotics & Antimicro Prot 11: 1248-1256

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!